EVECXIA THERAPEUTICS
Evecxia Therapeutics is a privately funded, clinical-stage pharmaceutical company that is dedicated to realizing the therapeutic potential of 5-hydroxytryptophan. It aims to develop and commercialize EVX-101, to treat patients suffering from disabling, common, and costly neuropsychiatric conditions in which current therapies are inadequate, in particular depression. The company was established in 2013 and is based in Raleigh, North Carolina.
EVECXIA THERAPEUTICS
Industry:
Health Care Pharmaceutical Therapeutics
Founded:
2013-01-01
Address:
Raleigh, North Carolina, United States
Country:
United States
Website Url:
http://www.evecxia.com
Total Employee:
11+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
15.12 M USD
Similar Organizations
Aimmune Therapeutics
Aimmune Therapeutics is a clinical-stage biopharmaceutical company that improves the lives of people with food allergies.
Amicus Therapeutics
Amicus Therapeutics is a biopharmaceutical company developing therapies for the treatment of rare and orphan diseases.
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Current Advisors List
Current Employees Featured
Founder
Official Site Inspections
http://www.evecxia.com
- Host name: ec2-18-222-195-17.us-east-2.compute.amazonaws.com
- IP address: 18.222.195.17
- Location: Columbus United States
- Latitude: 39.9653
- Longitude: -83.0235
- Metro Code: 535
- Timezone: America/New_York
- Postal: 43215
More informations about "Evecxia Therapeutics"
About Us - Evecxia Therapeutics
Evecxia Therapeutics - Crunchbase Company Profile & Funding
Evecxia Therapeutics is a pharmaceutical company that develops drugs to help patients suffering from disabling neuropsychiatric conditions. It aims to develop and commercialize EVX-101 to …See details»
Evecxia, Inc. - Drug pipelines, Patents, Clinical trials - Synapse
Explore Evecxia, Inc. with its drug pipeline, therapeutic area, technology platform, 14 news, and 1 literature, Disease Domain:Endocrinology and Metabolic Disease, Nervous System Diseases, …See details»
Evecxia Therapeutics, Inc. | LinkedIn
Evecxia Therapeutics, Inc. | 451 followers on LinkedIn. Harnessing the full therapeutic potential of serotonin synthesis amplification for the treatment of mental illness. | Evecxia is the first ...See details»
Evecxia Therapeutics Company Profile 2024: Valuation, Funding ...
Evecxia Therapeutics was founded in 2013. Where is Evecxia Therapeutics headquartered? Evecxia Therapeutics is headquartered in Durham, NC. What is the size of Evecxia …See details»
EVECXIA THERAPEUTICS, INC. Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for EVECXIA THERAPEUTICS, INC. of Westfield, IN. Get the latest business insights from Dun & Bradstreet.See details»
Evecxia Therapeutics - Contacts, Employees, Board Members, …
Organization. Evecxia Therapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 5. Number of …See details»
Evecxia Therapeutics Announces Leadership Transition to ... - Duke …
Evecxia is the first company dedicated to realizing the therapeutic potential of amplifying serotonin synthesis to treat disorders of the brain. Evecxia has two clinical stage drug candidates in …See details»
Evecxia Inc. - VentureRadar
Evecxia is a privately funded, clinical stage pharmaceutical company co-founded by Duke neuro-psychopharmacologists, Dr. Marc Caron and Dr. Jacob Jacobsen, located in the Research …See details»
Evecxia Therapeutics - Company Profile - Tracxn
Evecxia Therapeutics - Developer of therapies for treating CNS disorders. Raised a total funding of $9.85M over 2 rounds from 4 investors. Founded by Jacob Jacobsen and Marc Caron in the …See details»
Evecxia Inc. | North Carolina Biotech Center
Evecxia is developing drugs which amplify serotonin synthesis to treat neuropsychiatric conditions for which current therapies are inadequate. Company Location. https://www.evecxia.com. Find …See details»
Evecxia Therapeutics - Overview, News & Similar companies
Oct 2, 2023 Evecxia Therapeutics Reports No Toxicology Findings in Nonclinical GLP Studies of Adjunctive EVX-101 RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Evecxia …See details»
Evecxia Therapeutics, which just raised more funding, has new CEO
Sep 14, 2023 Earlier, Evecxia, a clinical-stage pharmaceutical company co-founded by two Duke neuro-psychopharmacologists, secured $2.4M from Miami-based Collage Venture …See details»
Evecxia Therapeutics Announces CEO Transition - Business Wire
Sep 14, 2023 Evecxia deploys 5-hydroxytryptophan (5-HTP), the natural serotonin precursor, delivered via proprietary drug delivery technologies to achieve sustained serotonin synthesis …See details»
EVX-101: A Breakthrough in Major Depressive Disorder Treatment
Oct 10, 2023 The World Health Organization’s projections for MDD becoming the leading cause of disease burden by 2030 underscore the urgency of innovative therapeutic interventions. In a …See details»
Evecxia Therapeutics and Quotient Sciences ... - World Pharma Today
Evecxia will now take the new EVX-101 drug candidate into a Phase 2 adjunctive treatment study in patients with MDD who are responding inadequately to a first-line SSRI/SNRI …See details»
Evecxia Inc. - VentureRadar
Evecxia Therapeutics is pioneering the therapeutic potential of serotonin synthesis amplification to treat mental illness. By focusing on 5-HTP, Evecxia aims to address inadequately treated …See details»
Evecxia Therapeutics and Quotient Sciences Complete Phase I …
Sep 28, 2023 Evecxia deploys 5-HTP, the natural serotonin precursor, delivered via proprietary drug delivery technologies to achieve sustained serotonin synthesis amplification. Evecxia has …See details»
Evecxia Therapeutics and Quotient Sciences Complete Phase I
Sep 25, 2023 Mark Egerton, PhD, CEO of Quotient Sciences, added how the partnership with Evecxia has greatly accelerated the development timeline of their EVX-101 program. …See details»